Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.

BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.

The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.

Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in...

Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in...

Updated Date: Fri, 06 Sep 2024 00:00:00 EDT

Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers

Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers

BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval...

BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval...